Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Aconitase 1 (ACO1) is a bifunctional cytosolic enzyme that acts both as an aconitase in the tricarboxylic acid (TCA) cycle and, under iron-deficient conditions, as a posttranscriptional regulator of iron metabolism by binding iron-responsive elements in mRNAs. When cellular iron is abundant, ACO1 incorporates a [4Fe-4S] cluster and catalyzes the conversion of citrate to isocitrate. When iron is scarce and the Fe-S cluster is lost, ACO1 switches to an RNA-binding form, regulating the stability and translation of mRNAs encoding key iron homeostasis proteins such as ferritin and the transferrin receptor. This dual function positions ACO1 as a critical sensor and effector in cellular iron balance, and its dysfunction is implicated in disorders of iron metabolism and some neurodegenerative diseases[1][2][3].
Not classically pharmacologically targeted; mechanistic action involves inhibition or modulation of enzymatic activity or protein–RNA binding, but no drugs directly approved or standardly used to target ACO1[1][2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Aconitase 1 (ACO1).